1415794-62-5

Basic information

• Product Name: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine hydrochloride
• Synonyms: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine hydrochloride
• CAS NO: 1415794-62-5
• Molecular Formula: C₁₆H₂₅BN₂O₂*ClH
• Molecular Weight: 324.66
• Mol File: 1415794-62-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine hydrochloride(1415794-62-5)
• EPA Substance Registry System: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine hydrochloride(1415794-62-5)

Safety Data

• Hazardous Substances Data: 1415794-62-5(Hazardous Substances Data)

Usage

Chemical structure

The compound has a unique chemical structure, featuring a phenyl ring with a 1,3,2-dioxaborolan-2-yl group attached to it, and a piperazine ring connected to the phenyl ring.

Solubility

The hydrochloride salt form of the compound increases its solubility in water, making it more suitable for use in various drug formulations.

Medicinal chemistry and pharmaceuticals

The compound is commonly used in the field of medicinal chemistry and pharmaceuticals due to its potential as a building block for the synthesis of new pharmaceutical compounds.

Piperazine derivative

The compound is a derivative of piperazine, a heterocyclic compound that is often used in the synthesis of various pharmaceuticals.

Biological targets

The compound can act as a ligand for various biological targets, making it a promising candidate for further research and development in the field of drug discovery and development.

Research and development

The unique chemical structure and properties of the compound make it a valuable candidate for further research and development in the field of drug discovery and development.

Potential applications

The compound has the potential to be used in the development of new drugs for various medical conditions, given its ability to act as a ligand for biological targets and its solubility in water.

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 352437-09-3 tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate 
• 470478-90-1 tert-butyl 4-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate 

Downstream Products

• 1422512-89-7 1-(p-[¹¹C]tolyl)piperazine 
• 1415794-51-2 (R)-tert-butyl 2-((7-(4-(piperazin-1-yl)phenyl)pyrido[4,3-b]pyrazin-5-ylamino)methyl)morpholine-4-carboxylate 
• 1089686-81-6 2-[4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-yl]ethan-1-ol 
• 1218791-38-8 1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)ethan-1-one 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS

The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.

Palladium-mediated conversion of para-aminoarylboronic esters into para-aminoaryl-11C-methanes

Cross-couplings are an alternative to conventional 11C- methylations which are generally employed in PET tracer synthesis. Therefore, we set out to develop a general procedure for the synthesis of para- 11CH3 labeled aromatic amines from the corresponding para-aminoarylboronic esters in the presence of free amines. Aryl boronic esters containing primary, secondary, and tertiary amines were successfully converted into corresponding labeled methyl derivatives in sufficient radiochemical yield to apply this method for tracer development. This procedure was applied to the labeling of CIMBI-712, a promising candidate for the in vivo imaging of the 5-HT7 receptor in the CNS.